Thalassaemia
Inherited haemoglobin disorders, including thalassaemia and sickle-cell disease, are the
most common monogenic diseases worldwide. Several clinical forms of α-thalassaemia and …
most common monogenic diseases worldwide. Several clinical forms of α-thalassaemia and …
β-Thalassemia
R Origa - Genetics in medicine, 2017 - nature.com
Abstract β-Thalassemia is caused by reduced (β+) or absent (β 0) synthesis of the β-globin
chains of hemoglobin. Three clinical and hematological conditions of increasing severity are …
chains of hemoglobin. Three clinical and hematological conditions of increasing severity are …
Non-transfusion-dependent thalassemias
KM Musallam, S Rivella, E Vichinsky… - …, 2013 - pmc.ncbi.nlm.nih.gov
Non-transfusion-dependent thalassemias include a variety of phenotypes that, unlike
patients with beta (β)-thalassemia major, do not require regular transfusion therapy for …
patients with beta (β)-thalassemia major, do not require regular transfusion therapy for …
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo …
Background In patients with non-transfusion-dependent β-thalassaemia, haemoglobin
concentrations lower than 10 g/dL are associated with a higher risk of morbidity, mortality …
concentrations lower than 10 g/dL are associated with a higher risk of morbidity, mortality …
How I manage medical complications of β-thalassemia in adults
The complex pathophysiology in β-thalassemia can translate to multiple morbidities that
affect every organ system. Improved survival due to advances in management means that …
affect every organ system. Improved survival due to advances in management means that …
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
Recent molecular studies of fetal hemoglobin (HbF) regulation have reinvigorated the field
and shown promise for the development of clinical HbF inducers to be used in patients with …
and shown promise for the development of clinical HbF inducers to be used in patients with …
[HTML][HTML] Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East
Abstract β-Thalassemia is one of the most common monogenetic diseases worldwide, with a
particularly high prevalence in the Middle East region. As such, we have developed long …
particularly high prevalence in the Middle East region. As such, we have developed long …
Optimal management of β thalassaemia intermedia
Our understanding of the molecular and pathophysiological mechanisms underlying the
disease process in patients with β thalassaemia intermedia (TI) has substantially increased …
disease process in patients with β thalassaemia intermedia (TI) has substantially increased …
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia
Background Patients with β thalassemia intermedia can have substantial iron overload,
irrespectively of their transfusion status, secondary to increased intestinal iron absorption …
irrespectively of their transfusion status, secondary to increased intestinal iron absorption …
Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia
In β-thalassemia, unequal production of α-and β-globin chains in erythroid precursors
causes apoptosis and inhibition of late-stage erythroid differentiation, leading to anemia …
causes apoptosis and inhibition of late-stage erythroid differentiation, leading to anemia …